Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Chemosphere
|
January 31, 2025
A polyethyleneimine-coated thermally-oxidized graphitic-carbon nitride adsorbent for the removal of organic pollutants
Wenhao Wang, Mengying Xu, Chun He, et al.
Journal of Medicinal Chemistry
|
May 25, 2012
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts
Roben G Gieling, Muhammad Babur, Lupti Mamnani, et al.
Magnetic Resonance in Medicine
|
September 1, 2017
Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI
Adam K Featherstone, James P B O'Connor, Ross A Little, et al.
The Journal of Biological Chemistry
|
August 29, 2012
Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor
Cristina Ferreras, Graham Rushton, Claire L Cole, et al.
Cancer Research Communications
|
September 6, 2024
Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action
James P B O'Connor, Victoria Tessyman, Ross A Little, et al.
Magnetic Resonance in Medicine
|
February 15, 2020
Diffusion model comparison identifies distinct tumor sub-regions and tracks treatment response
Damien J McHugh, Grazyna Lipowska-Bhalla, Muhammad Babur, et al.
Cancer Research
|
December 15, 2015
Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models
James P B O'Connor, Jessica K R Boult, Yann Jamin, et al.
Molecular Cancer Therapeutics
|
February 22, 2013
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941
Christopher Cawthorne, Natalie Burrows, Roben G Gieling, et al.
Plos One
|
February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Oncogene
|
July 14, 2020
Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer
Darrell Green, Heather Eyre, Archana Singh, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Chemosphere
|
January 31, 2025
A polyethyleneimine-coated thermally-oxidized graphitic-carbon nitride adsorbent for the removal of organic pollutants
Wenhao Wang, Mengying Xu, Chun He, et al.
Journal of Medicinal Chemistry
|
May 25, 2012
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts
Roben G Gieling, Muhammad Babur, Lupti Mamnani, et al.
Magnetic Resonance in Medicine
|
September 1, 2017
Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI
Adam K Featherstone, James P B O'Connor, Ross A Little, et al.
The Journal of Biological Chemistry
|
August 29, 2012
Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor
Cristina Ferreras, Graham Rushton, Claire L Cole, et al.
Cancer Research Communications
|
September 6, 2024
Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action
James P B O'Connor, Victoria Tessyman, Ross A Little, et al.
Magnetic Resonance in Medicine
|
February 15, 2020
Diffusion model comparison identifies distinct tumor sub-regions and tracks treatment response
Damien J McHugh, Grazyna Lipowska-Bhalla, Muhammad Babur, et al.
Cancer Research
|
December 15, 2015
Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models
James P B O'Connor, Jessica K R Boult, Yann Jamin, et al.
Molecular Cancer Therapeutics
|
February 22, 2013
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941
Christopher Cawthorne, Natalie Burrows, Roben G Gieling, et al.
Plos One
|
February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Oncogene
|
July 14, 2020
Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer
Darrell Green, Heather Eyre, Archana Singh, et al.
Page
of 3